Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05792150
Other study ID # WSG-NIS04 / PROOFS
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 7, 2022
Est. completion date June 2035

Study information

Verified date September 2023
Source West German Study Group
Contact Julian Moellers
Phone 00492161566 23-0
Email julian.moellers@wsg-online.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

There is only limited data for premenopausal patients in general, as well as for differences in the use of OFS in the subgroups of pre- and perimenopausal patients, respectively. The WSG ADAPT trial data on the impact of postmenopausal status and/or use of OFS within 3-4 weeks endocrine induction therapy show relevant impact of OFS/postmenopausal status on Ki-67 response; also, secondary amenorrhea after (neo-)adjuvant chemotherapy was a positive predictor of outcome due to OFS [8, 9]. This registry will give insights in the real-world use of OFS and the effect of secondary amenorrhea in female pre- and perimenopausal patients with or without previous use of chemotherapy and with different endocrine treatments (ET +/- GnRH). As adherence over time (5-10 years) plays a major role in the endocrine treatment, the registry will follow patients' treatments for up to 10 years and include QoL information. Results of MammaPrint® (MammaPrint® Index) as indicating factor for chemotherapy use and risk classification, thus, choice of adjuvant treatment (chemotherapy, OFS combined with endocrine therapy, or endocrine therapy alone) will be correlated to outcome under real-world conditions. Baseline, treatment, and relapse data shall be collected to gain further insight in the treatment paths, treatment adherence, and outcome of such patients.


Description:

This registry aims - to confirm an excellent outcome in pre-/perimenopausal patients treated by endocrine therapy (+ ovarian suppression) in patients with low genomic risk by MammaPrint® without chemotherapy use in a real-world setting. - to evaluate management of ovarian function in patients treated by adjuvant chemotherapy according to investigator decision. - to evaluate adherence to endocrine therapy (+/- ovarian function suppression). - to evaluate the prognostic impact of clinicopathological markers (e.g., estrogen receptor (ER), progesterone receptor (PR), HER2 receptor, Ki-67 at baseline and after preoperative endocrine therapy (if any performed) by local pathology assessment compared to genomic signature result. - to assess the course of quality of life (QLQ BR23 and QLQ-C30) until 5 years of treatment with OFS (Baseline, 3 months, 6 months, 12 months, 18 months, 2 years, 3 years, 4 years, 5 years) In general, WSG aim to assess the quality of surveillance care in younger breast cancer patients. WSG want to gain knowledge about endocrine induction treatment for indication of chemotherapy followed by endocrine treatment or endocrine treatment alone. Also, WSG aim at changes in duration of endocrine treatment (especially in high-risk patients up to 10 years) and introduction of intensified endocrine therapy (OFS) in combination with GnRH-analogues since publication of the SOFT and TEXT trials.


Recruitment information / eligibility

Status Recruiting
Enrollment 1470
Est. completion date June 2035
Est. primary completion date March 2035
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: Patients are eligible for participation in the registry only if they meet all the following criteria: - Female breast cancer patients - Pre- or perimenopausal at registry entry (age <60 years and state after hysterectomy or amenorrhea for <12 months; confirmation by blood hormone levels (FSH and estradiol in premenopausal range as per local normal range) recommended) - Primary tumor diagnosis not older than three months prior to inclusion (primary diagnosis defined as date of initial tumor biopsy) - Estrogen- and/or progesterone-receptor-positive/HER2 negative early breast cancer without any clinical signs of metastases - Adequate risk for recurrence: - intermediate clinical risk for recurrence, defined as (clinical in case of neoadjuvant treatment): - c/pT1 and - c/pN0 and - Ki-67 15-24% or - G2 or - patients, who do not meet these criteria but are at intermediate clinical risk for recurrence at investigator decision (e.g., very young age, low expression of hormone receptors, existing co-morbidities, familial cancer burden, etc.) can be included on individual decision basis or - high clinical risk for recurrence, defined as either (clinical in case of neoadjuvant treatment): - c/pT2-4 or - c/pN1 or - Ki-67 =25% or - G3 - Low genomic risk of recurrence by MammaPrint® (tested on treatment naïve tumor specimen) - Luminal-type by BluePrint® - Treatment according to standard-of-care (e.g., AGO Guidelines) planned or started (until completion of local therapy the latest (including started or completed endocrine induction therapy), started, or planned adjuvant or neoadjuvant treatment) - Availability of untreated tumor material (core biopsy if preoperative endocrine therapy performed or neoadjuvant treatment intended or surgery specimen) - Capability to give written informed consent - Nodal positive patients will be accepted to the registry up to 25% of the genomic low/ultralow-risk population (n=441). Exclusion Criteria: Patients will not be eligible for the registry for any of the following reasons: - Any other genomic testing, besides MammaPrint®, has been performed on the tumor material - Medical or psychological conditions that would not permit the patient to sign informed consent - Legal incapacity or limited legal capacity - Current participation in any interventional clinical trial which tests anticancer drugs, immunotherapeutics, or antibody treatment for any type of neoplasm - Non-compliance of the patient

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Germany Marienhospital Aachen Aachen NRW
Germany Klinikum St. Marien Amberg Amberg Bayern
Germany DRK Kliniken Berlin Köpenick Berlin
Germany Medionko - Praxisklinik Krebsheilkunde Frauen Berlin
Germany Gynäkologisches Zentrum Bonn NRW
Germany Universitätsklinikum Bonn Frauenheilkunde Bonn NRW
Germany Marienhospital, Klinik für Gynäkologie und Geburtshilfe Bottrop
Germany DIAKO Ev. Diakonie-Krankenhaus gemeinnützige GmbH Bremen
Germany St. Vincenz-Krankenhaus Datteln Datteln NRW
Germany Luisenkrankenhaus GmbH Co KG Düsseldorf NRW
Germany Marien Hospital Düsseldorf Düsseldorf NRW
Germany AGAPLESION Diakonie Hamburg Hamburg
Germany Asklepios Klinik Barmbek Hamburg
Germany Gynäkologische Praxisklinik Hamburg-Harburg Hamburg
Germany Klinikum Hanau GmbH Hanau Hessen
Germany ViDia Christliche Kliniken Karlsruhe Karlsruhe Baden-Wüttemberg
Germany Kliniken der Stadt Köln Köln NRW
Germany Helios Klinikum Krefeld, Zentrum für Ambulante Gynäkologische Onkologie - Studienabteilung Krefeld
Germany Brustzentrum Niederrhein, Johanniter Bethesda Krankenhaus Moenchengladbach NRW
Germany Klinikum der Universität München München Bayern
Germany Med. Zentrum f. Hämatologie und Onkologie München München Bayern
Germany Studienzentrum Onkologie Ravensburg Ravensburg Baden-Wüttemberg
Germany Mathias-Spital-Rheine Rheine NRW
Germany Klinikum Südstadt Rostock Mecklenburg-Vorpommern
Germany MKS St. Paulus Schwerte (ehemals Marienkrankenhaus) Schwerte
Germany Klinikum Traunstein, Frauenklinik Südostbayern Traunstein
Germany Praxisnetzwerk Hämatologie/int. Onkologie Troisdorf NRW
Germany Christliches Klinikum Unna gGmbH Unna NRW
Germany Evangelisches Krankenhaus Wesel GmbH Wesel NRW
Germany St. Josefs-Hospital Wiesbaden GmbH Wiesbaden Hessen
Germany Klinikum Worms Worms Rheinland-Pfalz
Germany Helios Klinikum Wuppertal Wuppertal NRW

Sponsors (2)

Lead Sponsor Collaborator
West German Study Group Agendia

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary 5-year distant recurrence-free interval (dRFI, according to STEEP criteria version 2.0) dRFIin all patients treated by (intensified) endocrine therapy alone (and with ovarian suppression in cases with enhanced clinical risk according to current AGO-recommendations) 5 years
Secondary 10-year dRFI dRFI, according to STEEP criteria 2.0, in all patients treated by (intensified) endocrine therapy alone (with ovarian suppression in cases with higher clinical risk) 10 years
Secondary 5-year dRFI dRFI, according to STEEP criteria 2.0,in all patients treated by SOC chemotherapy treatment followed by ET+/-OFS 5 years
Secondary 10-year dRFI dRFI, according to STEEP criteria 2.0,in all patients treated by SOC chemotherapy treatment followed by ET+/-OFS 10 years
Secondary 5-year dDFS distant disease-free survival (dDFS, according to STEEP 2.0) in all patients and all treatment groups (i.e., patients treated by ET alone, ET + GnRH, chemotherapy followed by ET, chemotherapy followed by ET + GnRH, OFS-treated patients) 5 years
Secondary 10-year dDFS distant disease-free survival (dDFS, according to STEEP 2.0) in all patients and all treatment groups (i.e., patients treated by ET alone, ET + GnRH, chemotherapy followed by ET, chemotherapy followed by ET + GnRH, OFS-treated patients)treatment followed by ET+/-OFS 10 years
Secondary 5-year OS overall survival (OS) in all patients and all treatment groups 5 years
Secondary 10-year OS overall survival (OS) in all patients and all treatment groups 10 years
Secondary 5-year breast cancer-free interval (BCFI, according to STEEP 2.0) BCFI in all patients and all treatment groups 5 years
Secondary 10-year breast cancer-free interval (BCFI, according to STEEP 2.0) BCFI in all patients and all treatment groups 10 years
Secondary EORTC quality of life questionnaire BR23 compare the course of Qol between baseline and further defined timepoints; 23 items, symptom scales/items and functional scales/items, all of the scales and single-item measures range in score from 0 to 100. A high score for the functional scales represents a high/healthy level of functioning, whilst a high score for the symptom scales represents a high level of symptomatology or problems. every 3 months within 1st year
Secondary EORTC quality of life questionnaire C30 compare the course of Qol between baseline and further defined timepoints; 30 items, 10 subscales, the higher the rating, the worse. every 3 months within 1st year
Secondary EORTC quality of life questionnaire BR23 compare the course of Qol between baseline and further defined timepoints; 23 items, symptom scales/items and functional scales/items, all of the scales and single-item measures range in score from 0 to 100. A high score for the functional scales represents a high/healthy level of functioning, whilst a high score for the symptom scales represents a high level of symptomatology or problems. every 6 months within 2nd year
Secondary EORTC quality of life questionnaire C30 compare the course of Qol between baseline and further defined timepoints; 30 items, 10 subscales, the higher the rating, the worse. every 6 months within 2nd year
Secondary EORTC quality of life questionnaire BR23 compare the course of Qol between baseline and further defined timepoints; 23 items, symptom scales/items and functional scales/items, all of the scales and single-item measures range in score from 0 to 100. A high score for the functional scales represents a high/healthy level of functioning, whilst a high score for the symptom scales represents a high level of symptomatology or problems. yearly until 5 years
Secondary EORTC quality of life questionnaire C30 compare the course of Qol between baseline and further defined timepoints; 30 items, 10 subscales, the higher the rating, the worse. yearly until 5 years
Secondary adherence to OFS and endocrine treatment Duration of intake of OFS and endocrine treatment in all patients 10 years
Secondary concordance between BluePrint®/MammaPrint® molecular subtyping results vs. pathological immune-histochemistry results concordance between BluePrint®/MammaPrint® molecular subtyping results and pathological immune-histochemistry results with respect to tumour type 10 years
Secondary endocrine response measured by post-endocrine Ki-67 post-endocrine Ki-67 (=10% and/or relative change vs. baseline) in patients treated by preoperative ET 10 years
Secondary 5-year iDFS in node-negative patients with ultralow MammaPrint node-negative patients with ultralow MammaPrint® treated by shorter duration of ET (2-3 years at investigator decision) 5 years
Secondary 10-year iDFS in node-negative patients with ultralow MammaPrint node-negative patients with ultralow MammaPrint® treated by shorter duration of ET (2-3 years at investigator decision) 10 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02480933 - Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens N/A
Completed NCT05000502 - Exercise, Gut Microbiome, and Breast Cancer: Increasing Reach to Underserved Populations N/A
Not yet recruiting NCT04863833 - Tomosymthesis for Breast Mass Lesion Characterization
Withdrawn NCT06145399 - A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer Early Phase 1
Suspended NCT01320488 - Breast Cancer in Young Women: Is it Different? N/A
Recruiting NCT02089854 - Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer Phase 4
Active, not recruiting NCT01741883 - Side Effect Prevention Training (SEPT) for Nocebo Effects in Breast Cancer Patients N/A
Recruiting NCT06144164 - A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer Phase 3
Recruiting NCT06331793 - Pulsed Electromagnetic Fields for Analgesia Post Mastectomy N/A
Recruiting NCT05439499 - This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer. Phase 3
Terminated NCT03836872 - Acupuncture for Joint Symptoms in Patients With Breast Cancer N/A
Recruiting NCT06332976 - PrefeRences And ChemoTherapy In Breast Cancer patiEnts
Completed NCT01671319 - Dose Dense TC + Pegfilgrastim Support for Breast Cancer Phase 2
Not yet recruiting NCT06092892 - IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases Phase 2
Recruiting NCT05586256 - Ultra-hypofractionated Radiotherapy in Breast Cancer Patients
Not yet recruiting NCT03153631 - Female Sexual Dysfunction in Breast Cancer Patients N/A
Active, not recruiting NCT03059875 - Place of Comprehensive Geriatric Assessment in Patients ≥ 75 Years Care, With Breast Cancer, After Screening With FOG (Oncology Geriatric Filter) N/A
Active, not recruiting NCT02088710 - Expectations and Side Effects of Endocrine Therapy in Women With Breast Cancer N/A
Terminated NCT01083641 - Estrogen for Triple Negative Breast Cancer Phase 2
Recruiting NCT05374161 - An Intervention for Female Breast CANcer: Acceptance and Commitment Therapy (I-CAN-ACT) for Depression and Physical Pain N/A